The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15–20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma....

Full description

Bibliographic Details
Main Authors: Hongmei Cui, Qinghui Wang, Duane D. Miller, Wei Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
VERU-111
vemurafenib-resistance
melanoma
ERK
akt
skp2
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.637098/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.637098/full

Similar Items